The anti-tumor effect of activation of AMPK has been postulated to occur through several distinct mechanisms, including inhibition of two major drivers of prostate cancer carcinogenesis, lipogenesis and the mTOR signalling pathway [21, 22], indicating that AMPK activators may offer an advantage over drugs targeting only one anti-tumor pathway. Here, MTOR is linked to prostate carcinoma.